EDIT Insider Trading Activity and SEC Form 4 Filings
EDIT insider trading summary
Over the past 12 months, insiders at Editas Medicine, Inc. (EDIT) reported 10 sales worth $49K by 3 insiders and no open-market purchases on SEC Form 4. Net insider selling was $49K.
Latest EDIT insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Sep 3, 2026 | Gilmore Neil O'Neill | CEO | Sell | $16K (5,124 @ $3.04) |
| Sep 3, 2026 | Linda Burkly | EVP, Chief Scientific Officer | Sell | $2K (709 @ $3.04) |
| Sep 3, 2026 | Amy Parison | SVP, Chief Financial Officer | Sell | $1K (453 @ $3.04) |
| Aug 3, 2026 | Amy Parison | SVP, Chief Financial Officer | Sell | $2K (678 @ $2.58) |
| Mar 3, 2026 | Gilmore Neil O'Neill | CEO | Sell | $11K (5,394 @ $2.02) |
| Mar 3, 2026 | Linda Burkly | EVP, Chief Scientific Officer | Sell | $2K (749 @ $2.02) |
| Mar 3, 2026 | Amy Parison | SVP, Chief Financial Officer | Sell | $957 (474 @ $2.02) |
| Dec 3, 2025 | Linda Burkly | EVP, Chief Scientific Officer | Sell | $2K (713 @ $2.15) |
| Dec 3, 2025 | Amy Parison | SVP, Chief Financial Officer | Sell | $993 (461 @ $2.15) |
| Dec 3, 2025 | Gilmore Neil O'Neill | CEO | Sell | $12K (5,603 @ $2.15) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.